Trials / Completed
CompletedNCT01809600
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 43 (actual)
- Sponsor
- Gachon University Gil Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.
Detailed description
Inclusion criteria 1. pathologically confirmed BL or BL-U by World Health Organization 2008 criteria 2. age \>20 yrs 3. received rituximab+chemotherapy as first-line treatment 4. with measurable or evaluable lesion 5. with complete set of clinical and laboratory data for the analysis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention (observational study) |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2013-03-13
- Last updated
- 2017-02-24
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01809600. Inclusion in this directory is not an endorsement.